Akademik Veri Yönetim Sistemi
26. ULUSAL ELEKTRON MİKROSKOPİ KONGRESİ, Eskişehir, Türkiye, 20 - 23 Eylül 2023, ss.1
Psoriasis is a common, chronic and recurrent inflammatory skin disease characterized by hyperproliferation of keratinocytes and infiltration of immune cells. Recently, it has been reported that NLRP3 inflammasome axis triggers inflammatory processes in the pathogenesis of psoriasis. Bergenin is an anti-inflammatory phenolic glycoside. In this study, it was aimed to examine the anti-psoriatic effects of Bergenin (BER), which is known to have immunomodulatory properties, in the NLRP3-ASC-SIRT1 axis, in the in vitro psoriasis model induced by imiquimod (IMQ) widely used in the induction of in vivo psoriasis model. In this study, CaCl2 and IMQ were used to induce an in vitro model of psoriasis in a human keratinocyte cell line (HaCaT). The effect of BER on cell viability was determined by MTT test. Morphological changes of HaCaT cells treated with BER IC50 dose were examined under a light microscope by performing H&E staining. In order to evaluate the effects of BER on the inflammasome pathway, NLRP3, ASC and SIRT1 expression levels were immunofluorescent staining and Mean Intensity (MI) values were measured with ImageJ(Fiji). BER IC50 dose was determined as 200±10 μM by MTT test. Morphological images showed a significant increase in cell number, cell-cell junction units and cell size in IMQ-induced keratinocytes. While the number of cells decreased in the BER IC50 dose group, apoptotic bodies characterized by pycnotic nuclei were detected. In analyzes with ImageJ (Mean Intensity), a significant decrease in NLRP3 and ASC expression intensities was found in BER treated cells compared to control group. On the other hand, it was observed that SIRT1 expression, which is known to have antiinflammatory effects, increased in BER-treated cells. Our results showed that BER i) induces cell death in the psoriasis model characterized by keratinocyte hyperproliferation, and ii) modulates inflammation related to psoriasis formation and progression via NLRP3-ASC-SIRT1 axis. These data are the first reported that Bergenin has anti-psoriatic effects through the inflammasome pathway. If effects of Bergenin are supported by further studies, it may be a therapeutic drug candidate in the treatment of psoriasis.
This research was funded by VAN YYU Scientific Research Projects Unit within doctoral project numbered TDK-2022-10132.
Key words: Psoriasis, Bergenin, Inflammasome, Imiquimod, HaCaT